ARCHIVES

Slow Accruing Trials Should Be Removed From High Priority Program, Broder Says

This article is from The Cancer Letter archive.

Vol. 18 No. 38 | October 2, 1992

Download PDF Visit The Full Archive

Related Articles

Adriamycin Update Discussed At Seminar

January 10, 1975

In Brief: President’s Request For NCI FY 1981 Budget: Same As 1980; New Clinical Study Section Option Open

December 14, 1979

In Brief: Adamson is Acting Frederick Director; Fischinger Heads Hollings Center; ASCO Has New Exec. Dir.

February 12, 1993

60 Minutes To Air Segment On The “Deception at Duke”

February 10, 2012

Funding Opportunities: NCI extends Deadline for Three RFAs

July 9, 1999

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006